Nanomedicine approaches for treatment of hematologic and oncologic malignancies

Table 2 Clinical trials on natural killer cells in hematological and solid tumors

Condition	Interventions	Phase	Ref.	Status
Solid tumor	ROBO1 CAR-NK cells	I/II	NCT03940820	Recruiting
Ewing sarcoma; Neuroblastoma; Rhabdomyosarcoma; Osteosarcoma; CNS tumors	Allogeneic HCT; Donor NK cell infusion	II	NCT02100891	Active, not recruiting
Brain and CNS tumors; leukemia; lymphoma; chronic myeloproliferative disorders; lymphoproliferative disorder multiple myeloma and plasma cell neoplasm; myelodysplastic syndrome; myelodysplastic/ myeloproliferative neoplasm; unspecified adult solid tumor, protocol specific	Donor NK cell infusion	I/II	NCT00823524	Completed
Malignant solid tumors	NK Immunotherapy	II	NCT02853903	Completed
Malignant solid tumors	NK Immunotherapy	I/II	NCT02857920	Completed
Multiple myeloma	CIML NK cells plus KP1237 and low dose IL-2	I/II	NCT04634435	Recruiting
Hematological malignancy;	NK cell infusion	I	NCT01853358	Completed
leukemia; lymphoma; myeloma; Hodgkin's disease	NK-92 cells	I	NCT00990717	Completed
Acute lymphoblastic leukemia; chronic lymphoblastic leukemia; B-cell lymphoma	Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells	I	NCT04796688	Recruiting
Leukemia; lymphoma	NK cell infusion	I	NCT01287104	Completed

NK: Natural killer.